论文部分内容阅读
[目的]观察血清BNP、cTnI水平变化,探讨药物干预作用机制,为慢性心力衰竭的诊断和治疗提供新的思路。[方法]将60例CHF患者随机分为治疗组和对照组,每组30例。对照组患者采用心力衰竭常规药物治疗,治疗组在对照组治疗的基础上加用曲美他嗪20mg,每天3次,两组均连续治疗4周,检测血清BNP和cTnI的水平变化。[结果]与治疗前相比,两组治疗后血清BNP及cTnI水平显著降低(P﹤0.05或P﹤0.01);治疗后与对照组相比,治疗组血清BNP及cTnI水平也有显著降低(P﹤0.05)。[结论]曲美他嗪能明显降低血清BNP及cTnI水平,改善CHF患者的心功能,血清BNP及cTnI联合应用,可作为评价CHF治疗效果的监控指标。
[Objective] To observe the changes of serum BNP and cTnI levels and to explore the mechanism of drug intervention to provide new ideas for the diagnosis and treatment of chronic heart failure. [Methods] 60 CHF patients were randomly divided into treatment group and control group, 30 cases in each group. Patients in the control group were treated with conventional drugs of heart failure. The treatment group was treated with trimetazidine 20 mg on the basis of the control group three times a day for two weeks. The two groups were treated continuously for 4 weeks. Serum levels of BNP and cTnI were measured. [Results] The levels of serum BNP and cTnI in both groups were significantly lower than those before treatment (P <0.05 or P <0.01), and the levels of serum BNP and cTnI in treatment group were significantly lower than those in control group after treatment <0.05). [Conclusion] Trimetazidine can significantly reduce serum BNP and cTnI levels, improve cardiac function in patients with CHF, and serum BNP and cTnI can be used as a monitoring index to evaluate the therapeutic effect of CHF.